Skip to content

Lung Function in Post-COVID-19 Nursing Home Residents

Associated Factors for Impaired Lung Function in Post-COVID Nursing Home Residents

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05866211
Enrollment
184
Registered
2023-05-19
Start date
2022-04-25
Completion date
2024-01-30
Last updated
2024-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Post-COVID-19 Syndrome

Brief summary

The coronavirus disease 2019 (COVID-19) took a toll in institutionalised older adults, who represent a vulnerable population in European countries. The aim of this study is to identify the predictive factors that worsens lung function in post-COVID nursing home (NH) residents. This is a multicenter case-control study in nursing homes of Osona (Catalonia), where individuals with worsened (cases) and normal (controls) lung function will be studied. The inclusion criteria are: female and male from 65 to 95 years old, preserved cognitive capacity and positive diagnosis of COVID-19 at least 3 months prior. We will assess sociodemographic variables, lung function \[spirometry\], fatigue \[Chalder Fatigue Scale\], frailty \[Clinical Frailty Scale\], and activities of daily living (ADL) \[modified Barthel index\].

Interventions

OTHERPrevious exposure to SARS-CoV-2

This is an observational study in which no intervention will be applied.

Sponsors

Catalan Board of Physiotherapists
CollaboratorUNKNOWN
University of Vic - Central University of Catalonia
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
65 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* male and female * preserved cognitive function * previous positive diagnosis of COVID-19 at a minimum of 3 months to the day of data collection * individuals living permanently in a nursing home

Exclusion criteria

* individuals in coma or palliative care * any contraindication to perform spirometry (severe hypertension, myocardial infarction in the past week, non compensated heart failure, etc).

Design outcomes

Primary

MeasureTime frameDescription
Lung functionThrough study completion, an average of 1 yearLung function will be assessed by spirometry.

Secondary

MeasureTime frameDescription
Anthropometric variablesThrough study completion, an average of 1 yearAnthropometric variables (weight and height) will be collected by means of a scale and a measuring tape, respectively.
Health variablesThrough study completion, an average of 1 yearHealth variables (history of comorbidities) will be collected directly in the medical records of each participant.
COVID-19 variablesThrough study completion, an average of 1 yearThe following variables related to COVID-19 will be collected from the medical records of each participant: diagnostic tests (PCR and serological test), suspicious case (symptoms of cough, fever, difficulty breathing, etc.), previous hospitalization for COVID-19 (yes/no, duration), use of mechanical ventilation during hospitalization (yes/no, duration) and vaccination (yes/no, type).
Sociodemographic variablesThrough study completion, an average of 1 yearSociodemographic variables (age, gender, length of institutionalization) will be collected through an interview.
FrailtyThrough study completion, an average of 1 yearFrailty levels will be assessed using the Clinical Frailty Scale (CFS).
Dependency levelsThrough study completion, an average of 1 yearDependency levels will be assessed using the Barthel modified index.
FatigueThrough study completion, an average of 1 yearFatigue levels will be collected using the Chalder Fatigue Scale (CFQ-11)

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026